SOLICITATION NOTICE
65 -- Reagents from Roche for CLIA Exome Sequencing
- Notice Date
- 1/6/2017
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2017-066-DM
- Archive Date
- 1/27/2017
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute (NHGRI) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Roche Diagnostics, 9115 Hague Road, Indianapolis, IN 46256-1025 to procure the following (BRAND NAME: ROCHE Diagnostics) Procurement: 1. SEQCAP EZ EXOME +UTR LIBRARY 48 RXN, Product Number: 06740308011, Quantity: Two. Background: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Institute of Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. NHGRI supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI also supports the training of investigators and the dissemination of genome information to the public and to health professionals. The NIH Intramural Sequencing Center (NISC), established in 1997, is a multi-disciplinary genomics facility that emphasizes the generation and analysis of DNA sequence. In addition to providing investigators at the NIH access to well established, high-throughput DNA sequencing, NISC works closely with NIH collaborators to explore the use and implementation of leading edge genomics technologies, molecular biology protocols and analytical procedures. NISC is a centralized research facility for performing high-throughput, large-scale DNA sequencing and sequence analysis. While it is currently feasible to sequence an entire genome it is quite expensive and unwieldy. A more cost-effective approach is to primarily target only the exons of genes. This method has proven to be an excellent approach to elucidating the critical variants in many rare diseases as well as more common Mendelian diseases. Purpose and Objective: NISC has been CLIA certified using Roche Diagnostics reagents. CLIA requires NISC to consistently use the same source of reagents. NISC performs exome sequencing on over 2000 samples annually for scientists throughout the NIH and is CLIA certified for exome sequencing. Roche is the sole source for SEQCAP EZ EXOME +UTR LIBRARY reagents and NISC is required to use these reagents in order to comply with CLIA regulations. Period of Performance : Delivered within 2-Weeks Upon Receipt of Award. Place of Performance : NIH NISC Location, Rockville, Maryland Contractor's Requirements : The kits are in a pre-configured format and are carefully quality controlled. Government Responsibilities : Store reagents at stated temperature by vendor. Inspection and Acceptance Requirements : • Upon arrival of reagents to destination, the package and contents must be undamaged. • Upon arrival of reagents to destination, the package and contents must be at proper temperature. Regulatory Authority : This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source and is not expected to exceed the simplified acquisition threshold, only one responsible source and no other supplies or services will satisfy agency requirements. Statutory Authority : This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Closing Statement : Industry Classification (NAICS) Code is 325413, In-Vitro Diagnostic Substance Manufacturing, and the Small Business Size Standard in number of employees: 1,250. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-93-1 (January 1, 2017). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by January 12. 2017 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2017-066-DM by 7:30 a.m. Eastern Time, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency, shall contained the following:." 1. Name of Contracting Organization; 2. Solicitation number; 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. North American Industry Classification System (NAICS) Code; and 7. DUNS, TIN or EIN Number.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2017-066-DM/listing.html)
- Place of Performance
- Address: NIH NISC Location, Rockville, Maryland, 20852, United States
- Zip Code: 20852
- Zip Code: 20852
- Record
- SN04365216-W 20170108/170106233747-13b95cf8df3139e24fdb5f633f9ca84e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |